22 Dec 2020
The Food and Drug Administration has approved the use of a new oral hormone therapy drug, Relugolix, for treating advanced prostate cancer in men.
CEO vacancy, The Pituitary Foundation (Bristol)
29 Apr 2024
Volunteer and Support Services Coordinator, The Pituitary Foundation (London)
29 Apr 2024
Graduate Teaching Assistant Vacancy, University of Reading
29 Apr 2024
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024